Amorfix Life Sciences and Dr. Cashman receive Canadian Government grant to develop treatments for Alzheimer's Disease



    TSX: AMF

    TORONTO, July 22 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company
focused on treatments and diagnostics for brain-wasting diseases and the
University of British Columbia (UBC), today announced a research collaboration
to develop Alzheimer's treatments based upon the discovery of misfolded
superoxide dismutase 1 (SOD1) protein in the brains of people with Alzheimer's
Disease. The research will be aimed at preclinical efficacy studies for both
antibody treatments and vaccines and will be conducted in Dr. Cashman's
laboratory at the Brain Research Center at the UBC in collaboration with
Amorfix scientists, and will be supported by a grant from the Canadian
Institutes for Health Research (CIHR).
    "Amorfix previously reported the discovery of misfolded SOD1 in
Alzheimer's patients. This CIHR funding will help initiate an aggressive
program to show that our proprietary antibodies and vaccines can be effective
in treating Alzheimer's disease," said Dr. Neil Cashman, Chief Scientific
Officer of Amorfix and a Professor of Medicine (Neurology) at UBC. "The
repeated recent failures of amyloid-removal agents in Alzheimer's clinical
trials strongly suggest that other brain-damaging pathways are important and
we believe misfolding of SOD1 plays a critical role in this pathway."
    "It is reassuring to receive the scientific validation by the CIHR Review
Panel of the merits of targeting SOD1 in Alzheimer's disease," said Dr. George
Adams, CEO of Amorfix Life Sciences. "We continue to advance our theranostics
business plan to develop both diagnostics and therapeutics against Alzheimer's
disease."
    SOD1 has a "Jekyll-and-Hyde" nature as it normally plays an important
protective role in detoxifying free radicals in the body, but when misfolded
can create lethal oxidative free radicals. Amorfix's technology targets
misfolded SOD1 through two approaches, a passive infusion of manufactured
monoclonal antibodies and an active immunization approach designed to elicit
the production of similar antibodies by the patient's own body. Amorfix's
technology is based on the premise that the misfolding and aggregation of SOD1
is a principal agent in the death of neurons that occurs in brain-wasting
diseases. Amorfix believes that if misfolded SOD1 can be specifically
recognized and its toxic activity neutralized by antibodies, brain-wasting
diseases could be effectively treated.
    CIHR will fund $227,500 in cash over one year with Amorfix contributing
the balance of the $900,000 program.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings;
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

    %SEDAR: 00022789E




For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890